Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT03659136CT.gov The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | — | Completed | — | — | — |
NCT02258451CT.gov Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02077933CT.gov Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | — | Completed | — | — | — |
NCT02057133CT.gov A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | — | Active Not Recruiting | — | — | — |
NCT01948960CT.gov Influence of Exceptional Patient Characteristics on Everolimus Exposure | — | Completed | — | — | — |
NCT01499160CT.gov Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01272141CT.gov A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT01088893CT.gov Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy | — | Unknown | — | — | — |
NCT01298713CT.gov Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00426530CT.gov Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00107016CT.gov Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Fudan University | Approved | B · 61 |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
| Eribulin Monomethanesulfonate | Fudan University | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →